Could chemoradiotherapy replace surgery for esophageal cancer?

NCT ID NCT07629817

Recruiting now Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether patients with esophageal cancer who respond well to initial drug therapy can safely avoid surgery and instead receive chemoradiotherapy to preserve their esophagus. Over 1,000 participants will be randomly assigned to either surgery or organ preservation. The goal is to see if the non-surgical approach offers similar cancer control and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Toripalimab, Nab-paclitaxel, Platinum-based Chemotherapy, Radiation
What this could lead to: If successful, this could show that many patients with esophageal cancer can avoid major surgery and keep their esophagus, with similar cancer control outcomes.
What could go wrong: This is a large Phase 3 trial, but it's still early to know if organ preservation is as effective as surgery. There is a risk of cancer recurrence or side effects from chemoradiotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.